MedPath

NKI Therapy Compared to Usual Care of Recurrent Esophagogastric Anastomotic Strictures

Not Applicable
Terminated
Conditions
Esophageal Stricture
Anastomotic Stenosis
Dilation of Esophagus Due to Disease
Registration Number
NCT04406428
Lead Sponsor
Radboud University Medical Center
Brief Summary

Rationale: The study hypothesizes that NKI followed by endoscopic bougie dilation therapy will result in an increased dysphagia-free period, a reduction of endoscopic procedures and dysphagia-related quality of life, and lower costs, when compared with the standard endoscopic bougie dilation (EBD) in recurrent esophagogastric anastomotic strictures.

Objective: To evaluate the efficacy and cost-effectiveness of needle-knife incision (NKI) followed by EBD compared to standard EBD in patients with recurrent esophagogastric anastomotic strictures.

Study design: This multicenter study is an randomized controlled trial in which NKI followed by EBD will be compared with standard EBD.

Study population: Patients with recurrent dysphagia (at least 1 and a maximum of 5 previous dilations) due to an anastomotic esophagogastric stricture that requires treatment with repeated endoscopic bougie dilations.

Intervention : The intervention to be investigated is the addition of NKI therapy to EBD to 18 mm esophageal diameter.

Main study parameters/endpoints: The primary outcome of this study will be EBD-free time during follow-up of 6 months. Secondary outcome parameters will be the number of endoscopic procedures for treatment of dysphagia, quality of life (QoL), cost-reduction and cost-effectiveness.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Recurrent intra- or extrathoracic benign esophagogastric anastomotic stricture after esophagectomy. The definition of a stricture is based on the Ogilvie Dysphagia score (severity of dysphagia), i.e. Ogilvie score ≥2 (= ability to swallow semi-solid food or worse (Appendix table 1)).
  • No patency for a standard endoscope (diameter < 10 mm)
  • The recurrent stricture has been previously treated with at least 1 to a maximum of 5 EBD sessions that reached an esophageal diameter of ≥16 mm.
  • The stricture should be suitable for endoscopic incision (stricture length ≤10 mm).
Exclusion Criteria
  • Benign esophageal stricture other than an esophagogastric anastomotic stricture.
  • Strictures with a morphology unsuitable for NKI, such as long (>1 cm), irregulair or tortuous strictures.
  • Previous endoscopic treatment of the esophageal stricture with steroid injection, incision therapy or stent placement within the past 3 months.
  • Previous stent placement post-esophagectomy for anastomotic leakage.
  • (Suspicion of) locally recurrent or metastasized esophageal cancer.
  • Persisting postoperative esophageal fistula.
  • Inability to discontinue anticoagulants or high-dose antiplatelet drugs at time of the baseline procedure. Low-dose aspirin (max. 100 mg/day) may be continued.
  • Known clotting disorder that cannot pre-procedural be corrected.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Dilation free time6 months

EBD-free time

Secondary Outcome Measures
NameTimeMethod
Cost-reduction6 months
Cost-effectiveness6 months
Endoscopic procedures6 months

Number of endoscopic procedures for treatment of dysphagia

QoL6 months

Quality of life

Trial Locations

Locations (1)

Radboudumc

🇳🇱

Nijmegen, Gelderland, Netherlands

Radboudumc
🇳🇱Nijmegen, Gelderland, Netherlands

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.